PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26461
Abstract: Myeloproliferative neoplasms (MPN) are chronic stem cell disorders characterized by enhanced proliferation of myeloid cells, immune deregulation, and drug resistance. JAK2 somatic mutations drive the disease in 50–60% and CALR mutations in 25–30% of cases.… read more here.
Keywords: jak2; v617f mutational; jak2 v617f; myeloproliferative neoplasms ... See more keywords
Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4197
Abstract: This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined… read more here.
Keywords: tumor mutational; smoking status; cancer; non small ... See more keywords
Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34333
Abstract: Cellular and intrinsic markers of sarcoma immunogenicity are poorly understood. To gain insight into whether tumor–immune interactions correlate with clinical aggressiveness, the authors examined the prognostic significance of immune gene signatures in combination with tumor… read more here.
Keywords: attributes immune; immune signatures; tumor mutational; prognostic attributes ... See more keywords
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.1002/gcc.23047
Abstract: Chromosomal aberrations are known to drive metastatic spread, but their profile is still elusive in carcinoma of unknown primary (CUP). Therefore, the aim of this study was to characterize the chromosomal aberration pattern in CUP… read more here.
Keywords: prognostic impact; unknown primary; tumor mutational; mutational burden ... See more keywords
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.04.015
Abstract: BACKGROUND Tumour mutational burden (TMB) estimated from whole exome sequencing or comprehensive gene panels has previously been established as predictive factor of response to immune checkpoint inhibitors (ICIs). Its predictive value for the efficacy of concurrent… read more here.
Keywords: tmb; tumour mutational; cancer; gene ... See more keywords
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.02.038
Abstract: Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive… read more here.
Keywords: biomarker immunotherapy; tumour mutational; biomarker; burden biomarker ... See more keywords
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100057
Abstract: Background Tumor mutational burden (TMB) and density of tumor-infiltrating lymphocytes (TIL) have been postulated as predictive biomarkers for immunotherapy. Therefore, we investigated the concordance of TMB and TIL of primary/extracranial renal cell carcinoma (RCC) specimens… read more here.
Keywords: renal cell; tumor mutational; cell carcinoma; brain ... See more keywords
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "European urology focus"
DOI: 10.1016/j.euf.2017.07.004
Abstract: Point mutations in the TERT gene promoter occur at high frequency in multiple cancers, including urothelial carcinoma (UC). However, the relationship between TERT promoter mutations and UC patient outcomes is unclear due to conflicting reports… read more here.
Keywords: tert; tert alterations; urothelial carcinoma; mutational burden ... See more keywords
Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
Sign Up to like & getrecommendations! Published in 2021 at "iScience"
DOI: 10.1016/j.isci.2021.102248
Abstract: Summary High tumor mutational burden (TMB) is associated with response to checkpoint blockade in several cancers. We identify pathogenic germline variants associated with increased TMB (GVITMB). GVITMB were found in 7 genes using a pan-cancer… read more here.
Keywords: immune checkpoint; tumor mutational; germline variants; checkpoint ... See more keywords
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.10.003
Abstract: Therapies that utilize immune checkpoint inhibition work by leveraging mutation-derived neoantigens and have shown greater clinical efficacy in tumors with higher mutational burden. Whether tumors with a low mutational burden are susceptible to neoantigen-targeted therapy… read more here.
Keywords: neoantigen specific; low mutational; specific cells; burden ... See more keywords
Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Urology"
DOI: 10.1016/j.urology.2020.10.030
Abstract: Pembrolizumab was recently approved for treatment of cancers with high tumor mutational burden (TMB). We conduct a focused literature review of TMB as a predictive biomarker. TMB quantifies the sum of non-synonymous coding mutations (typically… read more here.
Keywords: tumor mutational; biomarker; genitourinary cancers; tmb ... See more keywords